Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)

• Michelle C. Crank,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Eleanor M. P. Wilson,

  Current address: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Laura Novik,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Mary E. Enama,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Cynthia S. Hendel,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Wenjuan Gu,

  Affiliation Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, Maryland, 21702, United States of America

  ⨯
• Martha C. Nason,

  Affiliation Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Robert T. Bailer,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Gary J. Nabel,

  Current address: Sanofi US, Cambridge, Massachusetts, United States of America

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Adrian B. McDermott,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• John R. Mascola,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Richard A. Koup,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Julie E. Ledgerwood,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Barney S. Graham ,

  * E-mail: bgraham@nih.gov

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• VRC012 Study Team

  ¶Membership of the VRC 012 Study Team is listed in the Acknowledgements.

  ⨯